Pemvidutide and Zepbound approach weight loss differently. Pemvidutide, an investigational GLP-1 and glucagon drug, stands out for preserving muscle unusually well (most of the weight lost comes from fat), and produced about 15.6% weight loss in trials, but it isn’t approved or available. Zepbound (tirzepatide) is FDA-approved, produces up to roughly 21% weight loss, and can be prescribed today, including through TrimRx. Here’s how they compare and why one is a real choice right now.<\/p>\n
Pemvidutide activates the GLP-1 and glucagon receptors in a balanced 1:1 ratio. The glucagon component is thought to drive fat metabolism, especially in the liver, and pemvidutide has drawn attention for what its maker calls class-leading lean mass preservation, meaning a high share of the weight lost is fat rather than muscle. It’s a weekly injection still in development, with programs in both obesity and fatty liver disease.<\/p>\n
Zepbound is tirzepatide, a dual GLP-1 and GIP agonist given weekly. It has large completed trials, an FDA approval for obesity (and separately for sleep apnea), and a wide real-world track record.<\/p>\n
The headline numbers favor Zepbound on total weight loss, but pemvidutide has its own story. In the MOMENTUM trial<\/a> published in Diabetes in 2024, pemvidutide produced about 15.6% weight loss over 48 weeks, with a notably high proportion coming from fat rather than lean tissue. Zepbound, in its SURMOUNT trials, produced up to about 21%. So Zepbound wins on the scale, while pemvidutide’s distinguishing feature is body composition and its lipid and liver benefits.<\/p>\n Pemvidutide’s muscle-preservation profile is genuinely interesting, especially for anyone worried about losing lean tissue during weight loss. But it remains investigational, with its lead phase 3 program focused on fatty liver disease and its obesity development still progressing. It can’t be prescribed.<\/p>\n Zepbound is available now, with more total weight loss and a long safety record. TrimRx prescribes tirzepatide in both compounded and brand-name forms after a provider review, and muscle can be protected on any weight-loss drug through resistance training and adequate protein. You can see how to get started on the TrimRx homepage<\/a> or by taking the quiz<\/a>.<\/p>\n Consider a hypothetical patient focused on keeping muscle as he loses weight. Pemvidutide’s design appeals to him, but since it isn’t available, a practical alternative is tirzepatide paired with strength training and enough protein, which protects muscle while delivering larger weight loss now.<\/p>\n No. Pemvidutide is investigational, with its lead phase 3 program in fatty liver disease and its obesity program still in development. It cannot be prescribed today.<\/p>\n Zepbound produces more total weight loss (up to about 21% versus 15.6%), while pemvidutide’s edge is preserving muscle and improving lipids and liver fat. Zepbound is also available now, whereas pemvidutide is not.<\/p>\n Yes. TrimRx prescribes tirzepatide (the drug in Zepbound) in both compounded and brand-name forms, after a licensed provider reviews your health profile.<\/p>\n\n\n
\n \nFeature<\/th>\n Pemvidutide<\/th>\n Zepbound (tirzepatide)<\/th>\n<\/tr>\n<\/thead>\n \n Mechanism<\/td>\n GLP-1 and glucagon (1:1)<\/td>\n GLP-1 and GIP<\/td>\n<\/tr>\n \n Weight loss<\/td>\n ~15.6%<\/td>\n Up to ~21%<\/td>\n<\/tr>\n \n Standout trait<\/td>\n Strong muscle preservation, lipid and liver benefits<\/td>\n Highest weight loss among approved drugs<\/td>\n<\/tr>\n \n Status<\/td>\n Investigational, phase 3<\/td>\n FDA-approved<\/td>\n<\/tr>\n \n Availability<\/td>\n Not available<\/td>\n Available, including through TrimRx<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Why One Is a Real Choice Today<\/h3>\n
Frequently Asked Questions<\/h3>\n
Is pemvidutide available yet?<\/h4>\n
Is pemvidutide better than Zepbound?<\/h4>\n
Can I get Zepbound through TrimRx?<\/h4>\n